1 2 3 t e c H n i c a L r e P O r t S The B cell lymphoma-6 (Bcl-6) and Bcl-xL proteins are expressed in germinal center B cells and enable them to endure the proliferative and mutagenic environment of the germinal center.
The B cell lymphoma-6 (Bcl-6) and Bcl-xL proteins are expressed in germinal center B cells and enable them to endure the proliferative and mutagenic environment of the germinal center. By introducing these genes into peripheral blood memory B cells and culturing these cells with two factors produced by follicular helper T cells, CD40 ligand (CD40L) and interleukin-21 (IL-21), we convert them to highly proliferating, cell surface B cell receptor (BCR)-positive, immunoglobulin-secreting B cells with features of germinal center B cells, including expression of activation-induced cytidine deaminase (AID). We generated cloned lines of B cells specific for respiratory syncytial virus and used these cells as a source of antibodies that effectively neutralized this virus in vivo. This method provides a new tool to study B cell biology and signal transduction through antigen-specific B cell receptors and for the rapid generation of high-affinity human monoclonal antibodies.
Stable monoclonal cell lines of immortalized human B cells that express the BCR on their cell surface while secreting antibodies would be attractive tools not only for studying various aspects of BCR signaling but also for the generation of human monoclonal antibodies. BCR expression on polyclonal immortalized human B cells would facilitate selection of antigen-specific cells on the basis of binding of antigen to the specific BCR, whereas production of antibodies would enable selection of B cell clones on the basis of the functional activities of the secreted antibodies.
Mature B cells can be cultured in vitro with CD40L and cytokines such as IL-4, IL-10 or IL- 21 (refs. 1-3) . Whereas B cells cultured with CD40L, IL-2 and IL-4 produce very little immunoglobulin, addition of IL-21 leads to differentiation to plasma cells accompanied by high immunoglobulin secretion 4, 5 . Although this in vitro system has proven useful to study some aspects of B cell differentiation, both naive IgD + B cells and switched IgD − memory B cells eventually differentiate into terminally differentiated plasma cells, a process accompanied by cell cycle arrest precluding the generation of long-term, antigen-specific BCR + cell lines. We hypothesized that prevention of terminal differentiation would allow activated B cells to expand in vitro for much longer periods.
Recent advances have provided insight into how multiple transcription factors, including B lymphocyte-induced maturation protein-1, X-box-binding protein-1 and Bcl-6 control development of germinal center B cells into terminally arrested, antibody-producing plasma cells 6 . The transcriptional repressor Bcl-6 has been shown to prevent plasma cell differentiation in germinal center B cells, where it facilitates expansion of B cells by downregulating p53 and prevents premature differentiation of B cells into plasma cell by negatively regulating B lymphocyte-induced maturation protein-1 (refs. 5,7-10) .
Recently, we reported that forced expression of constitutively active signal transducer and activator of transcription-5 (STAT5) in B cells induced expression of both Bcl-6 and Bcl-xL and prevented terminal differentiation of B cells in vitro [11] [12] [13] . Here we show that ectopically expressed Bcl-6 and Bcl-xL synergize with CD40L and IL-21 to increase the proliferative lifespan of B cells in vitro. The expanded cells have features of germinal center B cells and express a functional BCR while secreting antibodies, providing a new and powerful tool to generate human BCR + , antibody-secreting B cell lines.
RESULTS

Transduction of memory B cells with Bcl-6 and Bcl-xL
To test whether Bcl-6 and Bcl-xL synergize to increase the proliferative and survival potential of B cells in vitro, we introduced the genes encoding these proteins into isolated human peripheral blood CD27 + memory B cells by retrovirus-mediated gene transfer. We cultured transduced cells on irradiated L cells expressing CD40L (CD40L-L cells) 1 2 4 volume 16 | number 1 | january 2010 nature medicine t e c H n i c a L r e P O r t S in the presence of IL-21, a factor produced by follicular helper T cells in the germinal center that strongly induces proliferation of B cells 3 . We visualized the transduced cells by their expression of a truncated form of the nerve growth factor receptor (∆NGFR) (for Bcl-6) and GFP (for Bcl-xL) ( Fig. 1a) . Cells expressing both Bcl-6 and Bcl-xL rapidly increased in frequency to more than 95% of the culture within a 2-week period ( Fig. 1b) and these cells showed a clear expansion advantage compared to cells expressing Bcl-6 or Bcl-xL alone (Fig. 1c) . Normal human B cells cultured with CD40L and IL-21 rapidly differentiate to antibody-producing plasma cells 4 , a process that is accompanied by a decreased expression of surface BCR and human leukocyte antigen-DR (HLA-DR) and an increased expression of CD38 (ref. 14) . In contrast, cells transduced with Bcl-6 alone and cells transduced with Bcl-6 and Bcl-xL both retained BCR expression and were HLA-DR high CD38 intermediate (Fig. 1d) , confirming that Bcl-6 inhibits B cell differentiation 12, 13 .
Flow cytometric analysis of the Bcl-6-and Bcl-xL-transduced CD27 + memory B cells expanded with CD40L and IL-21 revealed that they express CD19, CD20, CD21 and CD22, the activation markers CD25, CD30, CD70, CD80, CD86, CD95 and inducible T cell co-stimulator ligand, the cytokine receptors CD132 (γc) and IL-21R, and the BCR ( Fig. 2a ). In addition, they express activation-induced cytidine deaminase (AICDA) transcripts ( Fig. 2b) .
When we introduced Bcl-6 and Bcl-xL into B cells from nonhuman primates and mice by retrovirus-mediated gene transfer, we observed rapid expansion for at least 1 month in the presence of IL-21 and CD40L-expressing L cells ( Supplementary Fig. 1 ), similarly to transduced human B cells, indicating that Bcl-6 and Bcl-xL allow expansion of B cells of multiple species. 
Selection of B cell clones on the basis of antigen binding
The expression of the BCR should allow for isolation of antigenspecific B cells. Therefore, we isolated tetanus toxin-specific B cells from peripheral blood by flow cytometry using phycoerythrinlabeled tetanus toxoid ( Fig. 3a) and seeded the sorted cells at limiting cell numbers at one cell per two wells and one cell per one well into a 96-well plate. Within 2 weeks, 39 (frequency of 68%) tetanus toxin-specific B cell clones, positive for either IgGκ or IgGλ light chain, arose and were expanded further ( Fig. 3a,b) . Cloned cells cultured with CD40L and IL-21 maintained a very short doubling time of 35-40 h (Fig. 3c) , and could be maintained for extended periods of time, during which they remained tetanus toxin specific (>4 months, data not shown).
To examine whether the BCR on B cells transduced with Bcl-6 and Bcl-xL was functional, we cultured IgG + tetanus toxin-specific and nonspecific B cell lines in the absence of CD40L-L cells or IL-21 for 4 h. We then stimulated the rested cells with tetanus toxin antigen or a human IgG-specific F(ab) 2 antibody and analyzed them for phosphorylation (p) of extracellular signal-regulated kinase (ERK) 15 . Within 30 s after addition of tetanus toxin, we detected pERK in the tetanus toxin-specific cells but not in the control cells that did not bind tetanus toxin ( Fig. 3d) , indicating the presence of antigen-specific, functional, BCR-coupled signal transduction machinery in these cells. We detected pERK in both cell lines stimulated with the IgG-specific F(ab) 2 antibody ( Fig. 3d) . Addition of tetanus toxin or IgG-specific F(ab) 2 antibody to cells labeled with the calcium-sensing dye Indo-1 induced a rapid shift in the ratio of bound versus unbound Indo-1, indicating that tetanus toxin and IgG-specific F(ab) 2 antibody induce Ca 2+ flux (Fig. 3e) . These results show that the BCR expressed on the cell surface of memory B cells transduced with Bcl-6 and Bcl-xL is signaling competent.
Selection of B cell clones secreting neutralizing antibodies
The IL-21 used to expand CD27 + B cells transduced with Bcl-6 and Bcl-xL is a strong inducer of differentiation into immunoglobulin-secreting cells 4 . The transduced cells indeed secreted immunoglobulin ( Fig. 4a) , but the average production of IgG by cells transduced with Bcl-6 and Bcl-xL was lower than that of plasma cells, although it was higher than that of memory B cells ( Supplementary  Fig. 2) . Analysis of the IgG and IgM amounts produced by monoclonal cell lines in a 3-d culture revealed that all clones produced t e c H n i c a L r e P O r t S immunoglobulin (Fig. 4a) . The IgM-producing clones secreted five to six times more immunoglobulin than the IgG-producing clones (Fig. 4a ), which has also been observed in cultures with nontransduced memory B cells 16 . Given the relatively high amounts of secreted antibodies by B cells transduced with Bcl-6 and Bcl-xL, we examined whether we could select respiratory syncytial virus (RSV)-specific B cells on the basis of secretion of specific antibody. RSV is the most common cause of bronchiolitis and pneumonia among infants and children under 1 year of age and is a serious health problem for elderly people 17 . We transduced memory B cells from a healthy donor with Bcl-6 and Bcl-xL, seeded them at 100 cells per well and expanded them with CD40L-L cells and IL-21. After 2 weeks of culture, we collected the supernatants and screened them for the presence of RSV-neutralizing antibodies in a microneutralization experiment 18 . Of 384 cultures (100 cells per well), 31 prevented RSV infection of HEp2 cells. We subcloned the four microcultures with the highest neutralizing activity by limiting dilution. We then selected and characterized four monoclonal cell lines (D25, AM14, AM16 and AM23). We observed median half-maximal inhibitory concentrations (IC 50 ) against the RSV-A2 virus ranging from 2.1 ng ml −1 for D25 and AM14 and 4.3 ng ml −1 for AM23 to 145 ng ml −1 for AM16 ( Fig. 4b) . Three of the four antibodies showed substantially lower IC 50 values compared to palivizumab (IC 50 209 ng ml −1 ), a humanized monoclonal antibody that is currently used as prophylaxis in infants who are at high risk of developing pathology after infection with RSV 19 . In addition, all RSVspecific antibodies efficiently neutralized a primary RSV isolate X (RSV-X) (Fig. 4c) .
D25 antibody inhibits RSV infection in cotton rats
To test the in vivo neutralizing activity of D25 in a prophylactic setting, we infected cotton rats, the standard model to test RSV infectivity and pathogenicity with the primary isolate RSV-X 20 . We injected rats intramuscularly (i.m.) with various quantities of recombinant D25 (0.6, 0.15 and 0.04 mg per kg body weight), palivizumab (2.0 and 0.6 mg per kg body weight) or control IgG1 (2.0 mg per kg body weight) 1 d before intranasal inoculation with RSV-X (1 × 10 6 halfmaximal tissue culture infectious dose (TCID 50 ) per rat). Whereas palivizumab completely prevented in vivo viral replication at 2.0 mg per kg body weight, D25 showed the same efficacy already at a dose of 0.6 mg per kg body weight and was partially neutralizing at a dose of 0.15 mg per kg body weight (Fig. 4d) . These data show that D25 is functional and potent in reducing RSV replication also in vivo.
AID is active in cells transduced with Bcl-6 and Bcl-xL
Analysis of AICDA expression in 23 monoclonal cell lines by real-time PCR revealed a variable expression in different clonal cell lines (data not shown). Several clones expressed levels similar to those in germinal center tonsil B cells, whereas others expressed low levels of AICDA (Fig. 5a) . To determine whether AID is functional in the B cell clones, we subcloned the RSV-specific monoclonal B-cell line D25 by singlecell sorting and analyzed the genes encoding the immunoglobulin variable heavy chain region for the presence of mutations. Expression of AID did not result in genetic instability leading to growth arrest and cell death, as 63% of the wells that were seeded showed robust expansion (data not shown). After 3 weeks, we collected the culture supernatant of 108 subclones and isolated the RNA from the cells. Sequence analysis revealed a total of 184 IGVH mutations (107 unique mutations), resulting in an estimated mutation rate between 8.85 × 10 −5 and 5.14 × 10 −5 mutations per base pair per cell division, which is at the lower end of the estimated AID-mediated mutation rate in vivo (1 × 10 −3 to 1 × 10 −5 ) 21 . The IGVH genes of the individual subclones showed a variable number of mutations, with 65% of subclones harboring one to three mutations (of which 23% were silent), 11% harboring more than three mutations and 24% without mutations (Fig. 5b) . The 372-base pair IGVH gene of D25 contains 26 AID mutational hotspots (RGYW/WRCY; the underlined nucleotide is preferentially mutated by AID) that account for 30% of the total mutations. We observed mutations predominantly in the complementaritydetermining regions and framework region-3 (Fig. 5c) .
Although the supernatants of the majority of D25 subclones bound RSV-infected HEp2 cells similarly to recombinant D25, supernatants from some clones bound either less or more than D25 (Fig. 5d) . The differences in binding activities were associated with mutations in the VH regions.
For some applications, it would be desirable to inhibit AID to prevent accumulation of mutations in the immunoglobulin genes of B cell clones transduced with Bcl-6 and Bcl-xL. To achieve this, we took advantage of the fact that AID is regulated by the basic helixloop-helix transcription factor E47 (ref. 22) . We overexpressed the helix-loop-helix factor inhibitor of DNA binding-3 (Id-3), which is known to form transcriptionally inactive complexes with E47, thereby inhibiting AID expression in D25 cells 22 . Overexpression of Id-3 strongly reduced AICDA levels in the D25 cell line (Fig. 5e ) without influencing proliferation of the D25 cells (data not shown). Thus, modulation of Id-3 abundance provides a method to prevent AID-induced mutations in B cells transduced with Bcl-6 and Bcl-xL. 
DISCUSSION
Here we have described an efficient and rapid method for the generation of antigen-specific, BCR + B cell lines. By retroviral introduction of Bcl-6 and Bcl-xL, we converted peripheral blood memory cells into germinal center-like B cells that can be maintained for prolonged periods in culture. The cells transduced with Bcl-6 and Bcl-xL express markers for human germinal center B cells including AID, CD38, CXCR4 and inducible T-cell co-stimulator ligand; the latter has been shown to have a key role in germinal center formation 23 . AID was expressed in all clones that were derived from CD27 + peripheral blood memory cells transduced with Bcl-6 and Bcl-xL, but the level was variable. We did not observe isotype switching in these cells over time, indicating that AICDA expression by itself is insufficient to drive this process at least in the time frame and culture conditions we applied. However, we found somatic hypermutations at a relatively low frequency in the IGH genes of subclones of one RSV-specific B cell clone. These findings indicate that the requirements for AID-mediated somatic hypermutation and class-switch recombination are different 24, 25 .
Screening of the immunoglobulin-containing culture supernatant of D25 subclones on RSV-infected cells revealed variations in binding capacity, suggesting that the VH gene mutations of some subclones resulted in changes in the antigen-binding affinity. These data raise the possibility that ongoing AID-mediated mutational activity in B cell clones can be used to select higher (or lower) affinity clones, obviating the need for deliberate molecular engineering of the relevant immunoglobulin-encoding genes. It is conceivable that, in some cases, mutations in the immunoglobulin-encoding genes of established cloned B cell lines need to be avoided. Introduction of Id-3 into B cells that already overexpress Bcl-6 and Bcl-xL resulted in inhibition of AICDA expression, consistent with previously reported findings 22 . Thus overexpression of Id-3 should prevent ongoing AIDmediated mutational activity, if changes in the IGVH and IGVL genes are undesirable.
We previously showed that IL-21 was able to elicit immunoglobulin secretion from polyclonal Bcl-6-expressing B cells 13 . Whereas stable BCR expression allows for selection of antigen-specific B cells by binding of fluorescent-labeled antigen, the secreted immunoglobulin can be screened for functional activity. Both methods provide a tool for rapid isolation of potential therapeutic antibodies. Indeed, we were able to generate unique RSV-neutralizing antibodies within 3 months after initiation of the B cell cultures by direct functional screens after immortalization of B cells obtained from an RSVexposed individual.
Recently, another method of generating monoclonal antibodies from human B cells was described on the basis of Epstein-Barr virus (EBV) transformation of B cells activated with Toll-like receptor 9 antagonists 26 . Both that method 26 and ours use human B cells from pathogen-exposed individuals to select monoclonal antibodies against a variety of pathogens without the need for recent vaccination of the donors. However, in contrast to B cells transformed by EBV 27 , all B cell lines obtained with Bcl-6-and Bcl-xL-mediated genetic programming stably express high levels of a signaling-competent, membrane-bound BCR. This high level of cell surface BCR facilitates isolation of B cells on the basis of antigen binding, which greatly increases the frequency of antigen-specific cells and abrogates the need for extensive subcloning.
The fact that rare B cells can easily be cloned compares our method favorably with a recently described single-cell cloning approach used to isolate influenza-specific antibodies 28 . The feasibility of this technique depends on a relatively high frequency of antigen-specific B cells that can be obtained by vaccination or very recent exposure to a pathogen 28, 29 . As discussed above, expression of AID in the genetically modified clones may be used to select antibodies with higher affinities, providing an advantage compared to the EBV transformation and single-cell PCR methods as platforms to generate human monoclonal antibodies.
Another advantage of the method described here is that it can be used to obtain stable lines of B cells from species other than humans. We have shown here that Bcl-6-and Bcl-xL-transduced B cells from mice and nonhuman primates proliferate for at least 1 month in the presence of CD40L and IL-21. We also generated a series of cloned lines of mouse B cells (data not shown). It is, therefore, feasible to assume that our method will allow for expansion of antigen-specific B cells of multiple species, including rabbits and goats. Such lines cannot be obtained with EBV, although EBV can transform B cells from a variety of monkey species 30 .
The monoclonal cell lines that can be generated with this technology are very useful not only for generation of monoclonal antibodies but also for detailed mechanistic studies of BCR-mediated signal transduction induced by specific antigens. They may be used to study signaling of BCR variants that differ in affinity for antigens. Furthermore, these cell lines can be useful tools to study the effects of a variety of external signals such as antigen or cytokines on the function of AID and the induction of somatic hypermutation.
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ONLINE METhODS
B cell isolation. We obtained B cells from peripheral blood (Sanquin) by Ficoll separation and CD22 MACS microbeads (Miltenyi Biotech). Subsequently, we sorted these cells for the CD19 + CD3 − CD27 + IgM − IgA − phenotype (IgG memory cells) or the CD19 + CD3 − CD27 + IgG − IgA − phenotype (IgM memory cells) on a FACSAria (Becton Dickinson). We obtained tonsil B cells from routine tonsillectomies performed at the Department of Otolaryngology at the Academic Medical Center. The use of these tissues was approved by the Medical Ethical Committee of the Academic Medical Center and was contingent on informed consent.
Cell culture. We maintained B cells (2 × 10 5 cells ml −1 ) in Iscove's modified Dulbecco's medium (Gibco) containing 8% FBS (HyClone) and penicillinstreptomycin (Roche) supplemented with recombinant mouse IL-21 (25 ng ml −1 , R&D systems) and cultured them on γ irradiated (50 Gy) mouse L cell fibroblasts stably expressing CD40L (obtained from J. Banchereau) (CD40L-L cells, 10 5 cells ml −1 ). We used recombinant human IL-4 (R&D Systems) at 50 ng ml −1 and recombinant human IL-2 (R&D Systems) at 100 U ml −1 . We tested cells routinely by PCR for the presence of mycoplasma and EBV (data not shown).
Retroviral transduction.
The Bcl-6 and Id-3 retroviral constructs have been described previously 11, 31 . We cloned cDNA encoding human Bcl-xL into the LZRS retroviral vector that was described previously 32 . We performed transfections and produced amphotropic and ecotropic virus by Phoenix packaging cells as described previously 11, 12 and concurrently transduced memory B cells by retroviruses after activation on CD40L-L cells in the presence of recombinant mouse IL-21 for 36 h as before 13 , but then we centrifuged cells and virus at 20 °C for 60 min at 360g. Flow cytometry. We analyzed stained cells on an LSRII (BD) and processed flow cytometry data with FlowJo software (Tree Star). The antibodies are described in the Supplementary Methods.
Reverse transcription PCR.
We carried out quantitative RT-PCR with a BioRad iCycler and used the 2 −(∆∆CT) method to calculate relative mRNA expression levels normalized to actin. Primers for AICDA (encoding AID) were described previously 33 .
Enzyme-linked immunosorbent assay. We coated plates with either antibody to human IgG or IgM Fc fragment (Jackson ImmunoResearch Laboratories) at 5 µg ml −1 in PBS for 1 h at 37 °C or overnight at 4 °C and washed them in ELISA wash buffer (PBS, 0.5% Tween-20). We used 4% milk in PBS as a blocking agent before we added serial dilutions of cell culture supernatants and horseradish peroxidase (HRP)-conjugated detection antibodies (dilutions: 1 in 2,500 for HRP-conjugated IgG-specific antibody (Jackson); 1 in 5,000 for HRP-conjugated IgM-specific antibody (Jackson)). We used tetramethylbenzidine substrate solution (Biosource) for development of the ELISAs.
Immunoblotting. We lysed cells in Triton Lysis Buffer supplemented with HALT protease inhibitor (Roche) and 1 µM Na 2 VO 4 . We separated equal amounts of protein by 10% SDS-PAGE, transferred them to nitrocellulose and probed for them using antibody to phospho-ERK1/2 (on Thr202 and Tyr204) (Cell Signaling Technologies) and STAT3-specific antibody (Santa Cruz).
We used enhanced chemiluminescence (Pierce Biotechnology) and X-ray film (Hyperfilm, GE Healthcare Life Sciences) for detection. Calcium flux. We cultured transduced B cells for 2 d without CD40L-L cells in the presence of IL-21. Subsequently, we loaded the cells with 2 µM Indo-1 AM (Sigma-Aldrich). We measured fluorescence ratios of Indo-1 emission at 405 nm and 485 nm by flow cytometry on a FACSVantage SE (BD).
Respiratory syncytial virus culture and neutralization assay. We seeded 1 × 10 4 HEp2 cells in flat-bottom 96-well plates (Costar). The next day, we preincubated 100 TCID 50 of RSV A2 or X virus mixed with B cell culture supernatant for 30 min at 37 °C before adding it in triplicate to HEp2 cells for 1 h at 37 °C. After 2 d, we fixed the cells with 80% acetone and stained them with polyclonal HRP-conjugated antibody to RSV (Biodesign) and 3-amino-9-ethylcarbazole for detection and visualization of RSV plaques by light microscopy (plaques were counted).
Cloning of D25.
We isolated total RNA with the RNeasy mini kit (Qiagen), generated cDNA, performed PCR and cloned the heavy and light chain variable regions into the pCR2.1 TA cloning vector (Invitrogen). To rule out reverse transcriptase-or DNA polymerase-induced mutations, we performed several independent cloning experiments. To produce recombinant D25 monoclonal antibody, we cloned D25 heavy and light variable regions in frame with human IgG1 and κ constant regions into a pcDNA3.1 (Invitrogen)-based vector and transiently transfected 293T cells (American Type Culture Collection). We purified recombinant D25 from the culture supernatant with Protein A (Sigma-Aldrich).
Cotton rat experiments. We anesthetized 7-to 9-week-old cotton rats (Sigmodon hispidus, Charles River) with isoflurane, bled them and gave them 0.1 ml of purified monoclonal antibody per 100 g body weight by i.m. injection at doses of 2.0 or 0.6 mg per k body weight for palivizumab, 0.6, 0.15 or 0.04 mg per k body weight for D25 and 2.0 mg per k body weight for the control antibody. Twenty-four hours later, we anesthetized the rats and challenged them by intranasal instillation of 1 × 10 6 TCID 50 RSV-X (100 µl). Five days 34 later, we killed the rats and collected their lungs. We calculated lung virus titers per gram of lung tissue. We determined lung virus titers by standard TCID 50 culture assay; control prophylaxis reached a titer of 4.7 log TCID 50 g −1 whereas the lower limit of detection was 2.1 log TCID 50 g −1 . The Animal Experiment Committee of the Netherlands Vaccine Institute approved all procedures involving cotton rats. 
